Janux Therapeutics, Inc. (JANX)
Last Price$29.3(3.2%)
Market Cap$1,656.1M
JANX Rating
JANX Quality rating performance
JANX Intrinsic Value
Key Highlights:
As of Mar 11, 2025 JANX Relative Value is $19.5, which is overvalued by 33.2%, compared to current share price of $29.3.
As of Mar 11, 2025 JANX DCF Value is N/A, which is undervalued by N/A, compared to current share price of $29.3.
JANX Share Price History
1W (2.5%)
1M (19.0%)
6M (33.1%)
YTD 165.4%
1Y (26.8%)
3Y 68.6%
5Y 16.3%
10Y 16.3%
Share Price
Intrinsic Value
Drawdown
Total Return
vs SP500
vs NASDAQ
Crunching data... Almost there!
JANX Stock Metrics
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Base
$1,656.1M
$653.9M
$10.6M
($44.2M)
Shares Outstanding
57M
Employees
14K
Growth (CAGR)
N/A
N/A
(76.6%)
38.63%
Profitability
90.2%
(933.6%)
(651.6%)
(413.8%)
(417.2%)
64.0%
Intrinsic Value
$19.7 (32.8% overvalued)
N/A
$19.7
($40.8)
($50.1)
(100.0%)
(39.2%)
Valuation (LTM)
Return on Capital
Financial Health
$1,025.2M
($1,002.1M)
22.7x
Dividends
Earnings
Jan 01, 1970
MISS by 0.0%
BEAT by (36.1%)
(14.3%)
9 Beat & 1 Miss
JANX Stock Financials
JANX Income Statement Metrics
Annual
Quarterly
LTM
JANX Cash Flow Statement Metrics
Annual
Quarterly
LTM
Operating Cash Flow (OCF)
($43.8M) -13.4% YoY
Capital Expenditure (CAPEX)
($359.0K) -80.6% YoY
Free Cash Flow (FCF)
($44.2M) -15.7% YoY
JANX Income Statement Overview
Annual
Quarterly
LTM
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Dec'24
JANX Balance Sheet Overview
Annual
Quarterly
LTM
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Dec'24
Assets
Liabilities
Total assets
$1,061.5M
Current assets ($1,033.7M, 97.4% of total)
$1,025.2M (96.6%)
$0.0 (0.0%)
Other current assets
$8,493.0K (0.8%)
Non-current assets ($27.9M, 2.6% of total)
$0.0 (0.0%)
$24.2M (2.3%)
$0.0 (0.0%)
Other non-current assets
$3,700.0K (0.3%)
Financial position
($1,002.1M)
Cash & Short-term
Investments
Total Debt
JANX Stock Ratios
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
JANX Earnings Surprises
Crunching data... Almost there!
JANX Dividends
JANX Dividend Yield
Crunching data... Almost there!
JANX Dividend Per Share
3Y
10Y
30Y
Annual
Quarterly
LTM
Competing with JANX
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$1,656.1M | 5.9 | $19.7 32.8% overvalued | (26.8%) | $10.6M | ($44.2M) | 31.0% | (417.2%) | 90.2% | (413.0%) | 2.3% | |
$124.8B | 5.7 | $187.5 61.6% overvalued | 17.8% | $11.0B | ($790.3M) | 11.5% | (7.2%) | 86.1% | (15.0%) | 10.7% | |
$77.0B | 6.3 | $1,048.3 46.0% undervalued | (25.4%) | $14.2B | $3,597.2M | 8.3% | 25.3% | 84.5% | 25.7% | 5.7% | |
$34.4B | 5.8 | $123.0 78.8% overvalued | 50.8% | $2,258.9M | ($211.2M) | 127.3% | (9.4%) | 86.8% | (41.3%) | N/A | |
$30.7B | 5.2 | $91.8 61.6% overvalued | 60.1% | $2,248.2M | ($42.6M) | 23.0% | (1.9%) | 85.6% | (7.2%) | 1,931.9% | |
$24.0B | 5.9 | $191.1 94.2% undervalued | 2.2% | €2,751.1M | (€229.8M) | (28.0%) | (8.4%) | 80.3% | (37.8%) | 1.3% | |
$14.5B | 5.4 | $71.6 120.5% undervalued | 11.2% | $2,263.9M | $2,769.0M | (3.8%) | 122.3% | 73.9% | 14.5% | 73.6% | |
$13.8B | 7.7 | $542.2 78.1% undervalued | 22.0% | $2,877.4M | $1,080.6M | 23.6% | 37.6% | 89.2% | 65.4% | 4.7% | |
$13.4B | 6.7 | $46.9 33.5% overvalued | (18.0%) | $2,850.5M | $475.4M | 17.8% | 16.7% | 78.6% | 11.0% | 10.7% | |
$13.3B | 5.9 | $0.6 96.9% overvalued | 330.2% | $0.0 | ($142.1M) | N/A | N/A | N/A | (3,335.4%) | 1.9% | |
$1,846.9M | 5.5 | $2,745.6 1,111.0% undervalued | 39.9% | $3,316.8M | ($1,041.0M) | 50.5% | (31.4%) | 83.7% | (43.2%) | 32.1% |
FAQ
What is Janux Therapeutics, Inc. (JANX) stock rating?
As of today, Janux Therapeutics, Inc. has a stock rating of 6 (out of 10), which is considered Good.
is Janux Therapeutics, Inc. (JANX) a good stock to buy?
As of today, Janux Therapeutics, Inc. has a Good stock rating, which is 32.8% overvalued. According to Value Sense backtesting, stocks with similar profile tend to underperform the market by 4.6%.